|1.||Lee, Ho-Young: 16 articles (11/2015 - 02/2003)|
|2.||Chen, Yan: 9 articles (02/2015 - 07/2005)|
|3.||Kim, Kyu-Won: 8 articles (11/2015 - 06/2007)|
|4.||Hong, Waun Ki: 8 articles (04/2009 - 02/2003)|
|5.||He, Jing: 6 articles (02/2015 - 07/2005)|
|6.||Suh, Young-Ger: 5 articles (11/2015 - 06/2007)|
|7.||Pezzuto, John M: 5 articles (11/2005 - 02/2003)|
|8.||Murillo, Genoveva: 4 articles (10/2013 - 03/2003)|
|9.||Mehta, Rajendra G: 4 articles (10/2013 - 03/2003)|
|10.||Kim, Woo-Young: 4 articles (02/2009 - 11/2005)|
01/01/2008 - "Considering that HIF-1alpha is overexpressed in a majority of human cancers, deguelin could offer a potent therapeutic agent for cancer."
08/22/2013 - "In the present study, we aimed to evaluate the anti-metastatic potential of deguelin in vivo and in tumor growth factor-β1 (TGFβ1)-stimulated cells. "
01/01/2008 - "This study was designed to investigate the effects of deguelin on tumor growth and angiogenesis, and the mechanisms underlying the antitumor activities of deguelin. "
03/01/2001 - "To study the pharmacokinetics of deguelin, a naturally occurring potential cancer chemopreventive agent, in rats. "
08/15/1997 - "These data indicate that deguelin exhibits cancer chemopreventive effects in skin and mammary tumorigenesis models and that additional studies are warranted to characterize the cancer chemopreventive or chemotherapeutic potential of this substance more fully."
|2.||Lung Neoplasms (Lung Cancer)
11/01/2009 - "Hence, the aim of the present study was to assess the therapeutic efficacy of deguelin, a rotenoid isolated from several plant species, which has been reported to have chemopreventive and/or chemotherapeutic effects in skin, mammary, colon, and lung cancers. "
12/01/2005 - "Thus, deguelin appears to be a promising new preventive agent for lung cancer and may be considered for further studies in other animal models and in clinical trials."
01/01/2015 - "Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway."
04/01/2012 - "We investigated the effects of deguelin on DNA damage and associated gene expression in human lung cancer NCI-H460 cells in vitro. "
02/15/2009 - "Furthermore, combined treatment of radiation with deguelin significantly decreased the survival and angiogenic potential of radioresistant lung cancer cells in vitro. "
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/2013 - "To study the inhibitory effect of Akt inhibitor deguelin on PC-3 human prostate cancer cell lines and its possible mechanism. "
12/15/2011 - "Taken together our study indicates that deguelin may have translational potential as therapeutic agent for advanced or metastatic prostate cancer."
12/15/2011 - "The aim of our study was to elucidate the effect of deguelin on the growth of prostate cancer cells and its putative mechanism of action. "
06/01/2013 - "Akt inhibitor deguelin can inhibit the proliferation of PC-3 human prostate cancer cells by affecting the down-stream signal molecules GSK3P3 and betaDM2 in the Akt pathway."
06/01/2013 - "PC-3 human prostate cancer cells were cultured in deguelin at the concentrations of 10, 100, 500 and 1 000 nmol/L for 24, 48 and 72 hours, respectively. "
|4.||Breast Neoplasms (Breast Cancer)
05/10/2013 - "In this study, we investigated the antitumor effects of deguelin in several human breast cancer cells in vitro and in vivo. "
11/01/2009 - "These studies support the antiproliferative effects of deguelin in human breast cancer cells and, perhaps more importantly, illustrate novel actions by deguelin in the Wnt signaling pathway."
06/01/2008 - "In this study, we assessed the effect of deguelin on radiosensitization of human breast cancer cells and its possible mechanism. "
10/01/2013 - "These results provide rationale for developing Deguelin as a chemotherapeutic agent for triple negative breast cancer patients. "
01/01/2013 - "In this report we evaluated efficacy and mechanism of action of Deguelin in triple negative breast cancer cell lines. "
|5.||Body Weight (Weight, Body)
10/01/2013 - "There was no difference in the body weight, nor was there a difference in liver and spleen weights between vehicle treated-control and Deguelin-treated animals, which indicated that Deguelin was nontoxic at the dose used in the present study. "
03/10/2003 - "The mean number of ACF for the control group was 29.0 +/- 4.3, whereas the mean numbers of ACF in the deguelin groups were 24.8 +/- 2.7, 7.2 +/- 1.5 and 4.6 +/- 1.4 at doses of 2.5, 5.0 and 10.0 mg/kg body weight, respectively. "
08/15/1997 - "In the rat mammary tumorigenesis study, intragastric administration of 2 or 4 mg of deguelin/kg of body weight daily, 5 days/week, reduced tumor multiplicity from 6.8 tumors/rat in the control group to 5.1 or 3.2 tumors/animal, respectively. "
01/01/2013 - "Deguelin (2 or 4 mg/kg body weight), when injected intraperitoneally, reduced the in vivo tumor growth of MDA-MB-231 cells transplanted subcutaneously in athymic mice. "
08/15/1997 - "At the 4 mg of deguelin/kg of body weight dose level, the tumor latency period was significantly increased. "
|1.||Glycogen Synthase (Synthase I)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Nuclear Pore Complex Proteins (Nucleoporins)
|4.||nuclear pore complex protein 98
|5.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|6.||Proto-Oncogene Proteins c-akt (Protein Kinase B)
|9.||Proteins (Proteins, Gene)
|10.||NF-kappa B (NF-kB)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Investigational Therapies (Experimental Therapy)
|5.||Photochemotherapy (Photodynamic Therapy)